마이크로새틀라이트 불안정성-고(High) 진행성 자궁내막암 환자에서 펨브롤리주맙: KEYNOTE-158 연구 결과

O’Malley 등(목,)이 이 문제를 연구했다.

www.synapsesocial.com/papers/69de96fb7702a00918b0bd9f — DOI: https://doi.org/10.1200/jco.21.01874

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer· 2020 · 520 citations
2. Cancer Statistics, 2021· 2021 · 17,337 citations
3. Second-Line Therapy for Endometrial Cancer: The Need for Better Options· 2015 · 59 citations
4. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study· 2019 · 1,036 citations
5. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).· 2019 · 55 citations